"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 3 | 5 |
| 1997 | 2 | 3 | 5 |
| 1998 | 9 | 5 | 14 |
| 1999 | 1 | 0 | 1 |
| 2000 | 6 | 2 | 8 |
| 2001 | 6 | 2 | 8 |
| 2002 | 12 | 6 | 18 |
| 2003 | 2 | 9 | 11 |
| 2004 | 8 | 8 | 16 |
| 2005 | 10 | 6 | 16 |
| 2006 | 5 | 12 | 17 |
| 2007 | 8 | 11 | 19 |
| 2008 | 9 | 21 | 30 |
| 2009 | 6 | 10 | 16 |
| 2010 | 11 | 8 | 19 |
| 2011 | 3 | 3 | 6 |
| 2012 | 9 | 7 | 16 |
| 2013 | 10 | 9 | 19 |
| 2014 | 16 | 9 | 25 |
| 2015 | 13 | 15 | 28 |
| 2016 | 15 | 8 | 23 |
| 2017 | 19 | 11 | 30 |
| 2018 | 10 | 11 | 21 |
| 2019 | 7 | 11 | 18 |
| 2020 | 14 | 11 | 25 |
| 2021 | 11 | 11 | 22 |
| 2022 | 2 | 10 | 12 |
| 2023 | 1 | 9 | 10 |
| 2024 | 4 | 7 | 11 |
| 2025 | 6 | 7 | 13 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Evaluation of hematocrit-adjusted conversion strategies for mycophenolic acid and tacrolimus monitoring using volumetric absorptive microsampling in lung and renal transplant recipients. J Pharm Pharm Sci. 2026; 29:16123.
-
Risk Factors for Acute Rejection in Pediatric Lung Transplantation and Its Impact on Graft Failure. Pediatr Pulmonol. 2026 Mar; 61(3):e71547.
-
Iterative Modification and Finalization of a Patient Decision-Aid for Immunosuppressive Medication Treatment Decision-Making in Systemic Lupus Erythematosus by a Racially Diverse Patient Group. J Clin Rheumatol. 2026 Mar 01; 32(2):e42-e48.
-
Effective Management of a Rare Case of Pediatric ANCA-Associated Vasculitis With Rituximab and Mycophenolate Mofetil. Am J Case Rep. 2026 Jan 04; 27:e949274.
-
Dose optimization of lymph node-targeted cyclosporine-A for lupus-driven vasculopathy. J Control Release. 2026 Feb 10; 390:114553.
-
A composite endpoint for systemic sclerosis-associated interstitial lung disease: association with mortality in two clinical trial cohorts. Respir Res. 2025 Nov 28; 26(1):337.
-
Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial. JAMA. 2025 Oct 21; 334(15):1339-1348.
-
Patient outcomes from implementing a shared decision-making aid for systemic lupus erythematosus: a prospective implementation study. Lancet Rheumatol. 2026 Apr; 8(4):e253-e264.
-
Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis. Mult Scler Relat Disord. 2025 Dec; 104:106750.
-
Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options. J Natl Compr Canc Netw. 2025 09; 23(9).